Literature DB >> 6688193

Initial chemotherapy for clinically localized lymphomas of unfavorable histology.

T P Miller, S E Jones.   

Abstract

Forty-five patients with localized non-Hodgkin's lymphoma of unfavorable histologic type (41 patients had diffuse histiocytic, 2 had nodular mixed, and 2 had minimally nodular histiocytic lymphoma) were treated with initial chemotherapy (28 patients), including cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP), or with initial CHOP followed by involved field radiotherapy (17 patients). Patients were clinically staged and found to have stage I (7 patients), stage IE (8), stage II (12), and stage IIE (18). Despite the presence of potentially adverse prognostic factors, including age older than 65 yr (11 patients), bulky disease (17), gastrointestinal involvement (9), and "B" symptoms (4), 44 of 45 patients (98%) achieved a complete response. Forty-two patients (93%) are alive with a median follow-up time of 41 mo (range 3-128 mo). Thirty-eight patients (84%) remain continuously free of disease. Neither the pretreatment clinical features nor the type of treatment significantly influenced the outcome for patients treated with initial chemotherapy. Patients who failed treatment relapsed at distant sites or in initially involved sites whether or not they received radiotherapy. Initial treatment for localized lymphomas of unfavorable histology with chemotherapy regimens of proven curative potential in advanced disease is a successful treatment strategy and obviates the need for extensive staging. The role of involved field radiotherapy following initial chemotherapy needs to be defined.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6688193

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Modern management of non-Hodgkin's lymphoma.

Authors:  G M Mead; J M Whitehouse
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-06

Review 2.  Current guidelines for the management of aggressive non-Hodgkin's lymphoma.

Authors:  M Martelli; V De Sanctis; G Avvisati; F Mandelli
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

3.  A randomized trial of two types of adjuvant chemotherapy in radiotherapy-treated patients with clinical stages I and II high-grade non-Hodgkin's lymphoma.

Authors:  J Wagstaff; I Todd; D Deakin; P Wilkinson; J H Scarffe; M Harris; M Jones; D Crowther
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Management of localized non-Hodgkin's lymphoma.

Authors:  R G MacKenzie; J J Rusthoven
Journal:  CMAJ       Date:  1985-09-15       Impact factor: 8.262

5.  Effects of DNA ploidy patterns on the survival of patients with primary gastrointestinal lymphoma.

Authors:  A Okuda; H Suzuki
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

6.  Primary non-Hodgkin's lymphoma of the bone: a single institution experience.

Authors:  C Deshmukh; A Bakshi; P Parikh; R Nair; V Pai; S Gupta; A Shaikh; M Muckaden; K Naresh; T Saikia
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

7.  Primary lymphoma of the penis with rationale of treatment.

Authors:  R D Carter; R Smith; H D Alpern; B M Healey
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

8.  Non-Hodgkin's lymphomas presenting with gastrointestinal involvement.

Authors:  W Siegert; G Hackl; U Löhrs; D Huhn
Journal:  Klin Wochenschr       Date:  1985-01-15

Review 9.  Clinical aspects of early stage non-Hodgkin's lymphoma.

Authors:  G M Mead
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

10.  Involved field radiotherapy or chemotherapy in the management of stage I nodal intermediate grade non-Hodgkin's lymphoma.

Authors:  G M Jeffery; G M Mead; J M Whitehouse; R D Ryall
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.